1. Home
  2. NNOX vs TENX Comparison

NNOX vs TENX Comparison

Compare NNOX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NANO-X IMAGING LTD

NNOX

NANO-X IMAGING LTD

HOLD

Current Price

$0.64

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNOX
TENX
Founded
2011
1967
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical Electronics
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
71.1M
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
NNOX
TENX
Price
$0.64
$1.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
★ $29.67
AVG Volume (30 Days)
1.3M
★ 3.9M
Earning Date
04-20-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$147.55
N/A
Revenue Next Year
$81.13
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.66
$1.31
52 Week High
$4.71
$19.40

Technical Indicators

Market Signals
Indicator
NNOX
TENX
Relative Strength Index (RSI) 34.95 27.10
Support Level N/A $1.31
Resistance Level $0.81 $2.22
Average True Range (ATR) 0.07 0.12
MACD 0.00 0.32
Stochastic Oscillator 6.37 5.95

Price Performance

Historical Comparison
NNOX
TENX

About NNOX NANO-X IMAGING LTD

Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: